Covid-19 roundup: Fau­ci, Collins in­ter­vene to stop FDA plas­ma au­tho­riza­tion, cit­ing weak da­ta; Roche, Re­gen­eron try to take an­ti­bod­ies glob­al

The FDA has placed on hold an emer­gency au­tho­riza­tion for the use of plas­ma as a Covid-19 treat­ment fol­low­ing the in­ter­ven­tion of top fed­er­al health of­fi­cials who claimed the avail­able da­ta were too weak, ac­cord­ing to a re­port in the New York Times.

NI­AID clin­i­cal di­rec­tor H. Clif­ford Lane con­firmed the hold to the Times, adding plas­ma may still be au­tho­rized some­time in the fu­ture.

Much has been made about the prospect of uti­liz­ing do­nat­ed plas­ma from re­cov­ered Covid-19 pa­tients to treat those cur­rent­ly in­fect­ed with the dis­ease. The the­o­ry goes that an­ti­bod­ies in the plas­ma can help re­duce the time pa­tients spend in hos­pi­tals as well as mor­tal­i­ty rates if the treat­ment is ad­min­is­tered quick­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.